[Key Financial Data](index=1&type=section&id=Item%20I.%20Key%20Financial%20Data) [Key Accounting Data and Financial Indicators](index=1&type=section&id=Item%20I.%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q3 2021, the company's operating revenue decreased by 8.15% year-over-year, but net profit attributable to shareholders increased by 13.48% year-over-year, while cumulative year-to-date revenue slightly increased by 0.31% and net profit attributable to shareholders decreased by 8.73% Key Accounting Data and Financial Indicators | Indicator | Current Period (2021 Q3) | YoY Change in Current Period | Year-to-Date (2021 Q1-Q3) | YoY Change in Year-to-Date | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue (million yuan) | 604.89 | -8.15% | 1,826.31 | 0.31% | | Net Profit Attributable to Shareholders (million yuan) | 71.68 | 13.48% | 178.44 | -8.73% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) (million yuan) | 66.65 | 9.11% | 160.89 | -13.39% | | Net Cash Flow from Operating Activities (million yuan) | - | - | 85.21 | -17.81% | | Basic Earnings Per Share (yuan/share) | 0.06 | 20.00% | 0.15 | -6.25% | | Total Assets (billion yuan) | 6.13 | 2.58% (vs. end of prior year) | - | - | | Owners' Equity Attributable to Shareholders (billion yuan) | 4.22 | 2.91% (vs. end of prior year) | - | - | [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=Item%20I.%28II%29%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) From year-start to report end, the company's non-recurring gains and losses totaled 17.55 million yuan, primarily comprising government subsidies of 24.32 million yuan recognized in current profit and loss Non-Recurring Gains and Losses Items and Amounts | Item | Year-to-Date Amount (million yuan) | Explanation | | :--- | :--- | :--- | | Gains and losses from disposal of non-current assets | -1.40 | - | | Government subsidies recognized in current profit and loss | 24.32 | - | | **Total** | **17.55** | -- | [Analysis of Changes and Reasons for Key Financial Indicators](index=2&type=section&id=Item%20I.%28III%29%20Analysis%20of%20Changes%20and%20Reasons%20for%20Key%20Financial%20Indicators) During the reporting period, significant changes occurred in certain balance sheet, income statement, and cash flow statement items, including an 88.85% increase in investment properties due to construction, a 141.44% increase in other income from government grants, and a 115.32% decrease in net cash flow from financing activities due to increased bank loan repayments - Investment properties increased by **88.85%** compared to the end of the previous year, primarily due to an increase in investment properties under construction[8](index=8&type=chunk) - Trading financial assets decreased by **74.78%** compared to the end of the previous year, primarily due to a decrease in wealth management products held[8](index=8&type=chunk) - Other income increased by **141.44%** year-over-year, primarily due to an increase in government subsidies received during the current reporting period[10](index=10&type=chunk) - Credit impairment losses decreased by **1142.55%** year-over-year (indicating a significant increase in losses), primarily due to an increase in accounts receivable and a corresponding increase in credit impairment provisions[10](index=10&type=chunk) - Net cash flow from financing activities decreased by **115.32%** year-over-year, primarily due to an increase in bank loan repayments during the current reporting period[11](index=11&type=chunk) [Shareholder Information](index=3&type=section&id=Item%20II.%20Shareholder%20Information) [Common Shareholder Information](index=3&type=section&id=Item%20II.%28I%29%20Total%20Number%20of%20Common%20Shareholders%2C%20Number%20of%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%20and%20Shareholdings%20of%20Top%20Ten%20Shareholders) As of the end of the reporting period, the company had 45,006 common shareholders, with the largest shareholder, Wang Tianxiang, holding 24.00% of shares, some of which are pledged, and the top ten shareholders including the company's first employee stock ownership plan - The total number of common shareholders at the end of the reporting period was **45,006**[12](index=12&type=chunk) Top Ten Shareholders' Shareholdings | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Wang Tianxiang | Domestic Natural Person | 24.00% | 285,499,420 | | Jiang Chen | Domestic Natural Person | 2.53% | 30,062,100 | | Fuan Pharmaceutical (Group) Co., Ltd. - First Employee Stock Ownership Plan | Other | 1.83% | 21,774,713 | [Changes in Restricted Shares](index=4&type=section&id=Item%20II.%28III%29%20Changes%20in%20Restricted%20Shares) At the end of the reporting period, the company's total restricted shares were 246,494,372, a decrease of 18,500 shares from the beginning of the period, primarily due to executive lock-up shares, including 214,124,565 shares held by the largest shareholder, Wang Tianxiang Changes in Restricted Shares | Item | Number of Shares (shares) | | :--- | :--- | | Restricted shares at beginning of period | 246,512,872 | | Restricted shares released in current period | 18,500 | | Restricted shares increased in current period | 0 | | Restricted shares at end of period | 246,494,372 | - Restricted shares are primarily executive lock-up shares, where 75% of the total shares held by executives at the end of each year during their tenure are locked up according to regulations[15](index=15&type=chunk) [Other Significant Matters](index=6&type=section&id=Item%20III.%20Other%20Significant%20Matters) The company signed an agreement in August 2021 to repurchase 51% equity of its subsidiary Red Realty LLC for $93 million, payable in five installments; however, the first installment of $17 million has not yet been received, prompting the company to take measures to secure the payment - The company signed an "Equity Repurchase Agreement" for SHI YUAN ZHU to repurchase 51% equity of Red Realty LLC held by Fuan Tianheng (USA) Co., Ltd. for **$93 million**[16](index=16&type=chunk) - As of the disclosure date of this report, the company has not yet received the first installment of **$17 million** for the equity transfer as stipulated in the agreement[17](index=17&type=chunk) - The company will take measures such as communication, property preservation, and judicial litigation to protect its interests and will determine whether to accrue asset impairment provisions based on subsequent developments[17](index=17&type=chunk) [Quarterly Financial Statements](index=6&type=section&id=Item%20IV.%20Quarterly%20Financial%20Statements) [Financial Statements](index=6&type=section&id=Item%20IV.%28I%29%20Financial%20Statements) This section presents the consolidated balance sheet as of September 30, 2021, and the consolidated income statement and consolidated cash flow statement for the period from year-start to report end [Consolidated Balance Sheet](index=6&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of September 30, 2021, the company's total assets were 6.13 billion yuan, a 2.58% increase from the end of the previous year; total liabilities were 1.46 billion yuan; and total equity attributable to parent company owners was 4.22 billion yuan, a 2.91% increase from the end of the previous year Consolidated Balance Sheet | Item | September 30, 2021 (billion yuan) | December 31, 2020 (billion yuan) | | :--- | :--- | :--- | | Total Assets | 6.13 | 5.97 | | Total Liabilities | 1.46 | 1.42 | | Total Equity Attributable to Parent Company Owners | 4.22 | 4.10 | | Total Owners' Equity | 4.67 | 4.56 | [Consolidated Income Statement from Year-Start to Report End](index=9&type=section&id=2.%20Consolidated%20Income%20Statement%20from%20Year-Start%20to%20Report%20End) In the first three quarters of 2021, the company achieved total operating revenue of 1.83 billion yuan, largely consistent with the prior year, while total operating costs increased, resulting in a net profit attributable to parent company owners of 178.44 million yuan, an 8.73% year-over-year decrease, with basic earnings per share at 0.15 yuan Consolidated Income Statement from Year-Start to Report End | Item | Current Period (2021 Q1-Q3) (billion yuan) | Prior Period (2020 Q1-Q3) (billion yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 1.83 | 1.82 | | Operating Profit | 0.20 | 0.23 | | Total Profit | 0.195 | 0.228 | | Net Profit Attributable to Parent Company Owners | 0.178 | 0.195 | | Basic Earnings Per Share (yuan/share) | 0.15 | 0.16 | [Consolidated Cash Flow Statement from Year-Start to Report End](index=10&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement%20from%20Year-Start%20to%20Report%20End) In the first three quarters of 2021, net cash flow from operating activities was 85.21 million yuan, a 17.81% decrease year-over-year; net cash flow from investing activities was -250.81 million yuan, indicating increased outflows; and net cash flow from financing activities turned negative at -41.84 million yuan, with cash and cash equivalents at 598 million yuan at period-end Consolidated Cash Flow Statement from Year-Start to Report End | Item | Current Period (2021 Q1-Q3) (million yuan) | Prior Period (2020 Q1-Q3) (million yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 85.21 | 103.67 | | Net Cash Flow from Investing Activities | -250.81 | -276.54 | | Net Cash Flow from Financing Activities | -41.84 | 273.10 | | Net Increase in Cash and Cash Equivalents | -208.68 | 93.84 | [Explanation of Financial Statement Adjustments](index=12&type=section&id=Item%20IV.%28II%29%20Explanation%20of%20Financial%20Statement%20Adjustments) The company adopted the revised Lease Accounting Standard (CAS 21) from January 1, 2021, but this accounting policy change had no significant impact on its consolidated financial statements, thus no adjustments were made to the opening financial statements for 2021 - The company adopted the new lease accounting standard from **January 1, 2021**, but this accounting policy change had no significant impact on its consolidated financial statements[31](index=31&type=chunk) [Audit Opinion](index=15&type=section&id=Audit%20Report) The company's 2021 third-quarter report is unaudited - The company's third-quarter report is **unaudited**[32](index=32&type=chunk)

福安药业（集团）股份有限公司 2021 年半年度报告全文 2021 年 08 月 福安药业（集团）股份有限公司 2021 年半年度报告全文 福安药业（集团）股份有限公司 1 第一节 重要提示、目录和释义 2021 年半年度报告 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚假记载、误导性 陈述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证本半年度报告中财 务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司特此声明：如本半年度报告中涉及未来计划等前瞻性陈述，该计划不构成公司对投资者的实质承诺，投资者及相关 人士均应对此保持足够的风险认识，并且应当理解计划、预测、与承诺之间的差异。 1、行业政策、研发风险 随着"医保控费"、 "化学仿制药一致性评价"、"集中带量采购"等政策的出台和逐步实施，对公司药品生产、研发、销 售等环节产生重大影响。药品价格仍然存在下降空间，药品市场开拓、销售压力加大。行业竞争将从销售环节转移至研发、 生产环节。在国家政策鼓励医药企业创 ...

[Important Notice](index=2&type=section&id=Important%20Notice) [Board of Directors' Statement](index=2&type=section&id=Board%20of%20Directors'%20Statement) The company's management confirms the authenticity, accuracy, and completeness of this quarterly report and assumes legal responsibility - The company's management confirms the report is **true, accurate, and complete**, and assumes legal responsibility[5](index=5&type=chunk) - All directors attended the board meeting to review this quarterly report[6](index=6&type=chunk) - The company's legal representative, chief accountant, and head of the accounting department guarantee the authenticity, accuracy, and completeness of the financial statements[6](index=6&type=chunk) [Company Profile](index=3&type=section&id=Company%20Profile) [Key Accounting Data and Financial Indicators](index=3&type=section&id=Key%20Financials) Revenue grew 13.52% year-over-year, but net profit attributable to shareholders decreased by 10.04%, with operating cash flow turning negative 2021 Q1 Key Financial Indicators | Indicator | Current Period | Same Period Last Year | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 649,322,674.71 | 571,998,133.15 | 13.52% | | Net Profit Attributable to Shareholders (RMB) | 61,530,042.45 | 68,396,960.97 | -10.04% | | Net Cash Flow from Operating Activities (RMB) | -11,859,300.03 | 28,689,443.33 | -141.34% | | Basic Earnings Per Share (RMB/Share) | 0.05 | 0.06 | -16.67% | | Weighted Average Return on Equity | 1.49% | 1.70% | -0.21% | | **Indicator** | **End of Current Period** | **End of Last Year** | **Change from Last Year-End** | | Total Assets (RMB) | 6,116,878,895.09 | 5,972,794,421.99 | 2.41% | | Net Assets Attributable to Shareholders (RMB) | 4,162,589,148.68 | 4,100,195,667.69 | 1.52% | - Non-recurring gains and losses for the period totaled **RMB 6.69 million**, primarily from government subsidies[10](index=10&type=chunk)[11](index=11&type=chunk) [Shareholder Information](index=4&type=section&id=Shareholder%20Information) As of the reporting period end, the company had 46,941 common shareholders, with the largest shareholder holding a 24.00% stake - At the end of the reporting period, the total number of common shareholders was **46,941**[13](index=13&type=chunk) Top Five Shareholders | Shareholder Name | Shareholder Type | Shareholding Ratio | Number of Shares | | :--- | :--- | :--- | :--- | | Wang Tianxiang | Domestic Natural Person | 24.00% | 285,499,420 | | Jiang Chen | Domestic Natural Person | 2.53% | 30,062,100 | | Fuan Pharmaceutical (Group) Co., Ltd. - Phase I Employee Stock Ownership Plan | Other | 1.83% | 21,774,713 | | Sun Guanghui | Domestic Natural Person | 0.94% | 11,155,918 | | Huang Tao | Domestic Natural Person | 0.93% | 11,123,442 | [Changes in Restricted Shares](index=5&type=section&id=Changes%20in%20Restricted%20Shares) Total restricted shares decreased from 248.75 million to 246.51 million, mainly due to the release of certain executive lock-up shares - During the reporting period, total restricted shares decreased from **248,752,772 to 246,512,872**, a net reduction of 2,239,900 shares[18](index=18&type=chunk) - Shareholders Huang Tao and Ma Jin had **2,250,000** and **63,900** restricted shares released, respectively, during the period[17](index=17&type=chunk) [Significant Matters](index=8&type=section&id=Significant%20Matters) [Significant Changes in Key Financial Data and Their Reasons](index=8&type=section&id=Analysis%20of%20Financial%20Changes) The company experienced significant financial metric fluctuations, including changes in financial assets, investment properties, operating expenses, and cash flow [Analysis of Changes in Balance Sheet Items](index=8&type=section&id=Balance%20Sheet%20Changes) Key balance sheet changes include a decrease in trading financial assets, an increase in investment properties, and shifts in payables and long-term debt - **Trading financial assets** decreased by **73.32%** from the beginning of the period, mainly due to the redemption of wealth management products by a subsidiary[21](index=21&type=chunk) - **Investment properties** increased by **84.08%**, primarily from increased investment in the plant construction project of the US subsidiary RED REALTY LLC[21](index=21&type=chunk) - **Notes payable** decreased by **63.06%** due to the settlement of matured notes[21](index=21&type=chunk) - **Employee compensation payable** decreased by **67.02%** following the payment of prior-year annual bonuses[21](index=21&type=chunk) - **Long-term borrowings** grew by **43.78%** as a subsidiary secured new long-term loans[21](index=21&type=chunk) [Analysis of Changes in Income Statement Items](index=8&type=section&id=Income%20Statement%20Changes) Notable income statement changes include increased administrative and R&D expenses, higher other income from subsidies, and a rise in credit impairment losses - **Administrative expenses** rose by **35.82%** YoY, driven by increases in employee compensation, professional service fees, maintenance costs, and intangible asset amortization[22](index=22&type=chunk) - **R&D expenses** increased by **34.06%** YoY due to greater investment in research and development activities[22](index=22&type=chunk) - **Other income** grew by **62.88%** YoY, mainly from an increase in government subsidies received[22](index=22&type=chunk) - **Credit impairment losses** increased by **199.39%** YoY, primarily due to higher provisions for credit losses resulting from a significant increase in accounts receivable[22](index=22&type=chunk) [Analysis of Changes in Cash Flow Statement Items](index=9&type=section&id=Cash%20Flow%20Changes) Net cash flow from operating activities declined by 141.34%, shifting from a net inflow to a net outflow due to increased operational expenses - Net cash flow from operating activities was **-RMB 11.86 million**, a decrease of RMB 40.55 million or **141.34%** from the prior period, mainly due to a RMB 70.12 million increase in cash outflows for period expenses, labor costs, and taxes[24](index=24&type=chunk) [Business Review and Outlook](index=9&type=section&id=Business%20Review%20and%20Outlook) Revenue grew 13.52%, but net profit fell 10.04% due to higher expenses, while key products passed consistency evaluations, enhancing competitiveness - During the period, the company achieved operating revenue of **RMB 649 million**, a YoY increase of **13.52%**, while net profit attributable to the parent company was **RMB 61.53 million**, a YoY decrease of **10.04%**, primarily due to increased investments in period expenses and R&D[25](index=25&type=chunk) - Key R&D progress: Cefminox Sodium for Injection was the first to pass the generic drug consistency evaluation, and Esomeprazole Sodium for Injection also passed, which will enhance the market competitiveness of these products[26](index=26&type=chunk) - The company faces key risks including industry policy changes, R&D failure, safety and environmental issues, and goodwill impairment, which will be addressed through enhanced policy research and product structure optimization[29](index=29&type=chunk) [Use of Raised Funds](index=11&type=section&id=Use%20of%20Raised%20Funds) The company reallocated RMB 30 million of raised funds from a high-risk R&D project to two new drug development initiatives Overview of Raised Fund Utilization (Unit: RMB Million) | Item | Amount | | :--- | :--- | | Total Raised Funds | 674.41 | | Funds Invested in Q1 | 0.89 | | Cumulative Funds Invested | 651.76 | - The "Zhichu Pharmaceutical New Product R&D Project" underwent significant changes; development of three original products was terminated due to manufacturing difficulties, policy changes, or poor clinical results[34](index=34&type=chunk) - The company has reallocated the **RMB 30 million** in raised funds from the three terminated products to the R&D of Alpha-Lipoic Acid tablets and Febuxostat tablets[34](index=34&type=chunk) [Financial Statements](index=14&type=section&id=Financial%20Statements) [Consolidated Balance Sheet](index=14&type=section&id=Consolidated%20Balance%20Sheet) As of March 31, 2021, total assets reached RMB 6.12 billion, and equity attributable to parent company owners was RMB 4.16 billion Key Items of Consolidated Balance Sheet (Unit: RMB) | Item | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | Total Assets | 6,116,878,895.09 | 5,972,794,421.99 | | Total Liabilities | 1,498,005,289.50 | 1,417,726,154.08 | | Equity Attributable to Parent Company Owners | 4,162,589,148.68 | 4,100,195,667.69 | | Total Liabilities and Equity | 6,116,878,895.09 | 5,972,794,421.99 | [Consolidated Income Statement](index=19&type=section&id=Consolidated%20Income%20Statement) For Q1 2021, the company generated total operating revenue of RMB 649 million, with net profit attributable to parent company shareholders at RMB 61.53 million Key Items of Consolidated Income Statement (Unit: RMB) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | I. Total Operating Revenue | 649,322,674.71 | 571,998,133.15 | | II. Total Operating Costs | 603,399,740.90 | 516,110,062.27 | | III. Operating Profit | 68,689,017.19 | 76,970,088.40 | | IV. Total Profit | 68,082,219.88 | 76,705,601.58 | | Net Profit Attributable to Parent Company Shareholders | 61,530,042.45 | 68,396,960.97 | [Consolidated Cash Flow Statement](index=23&type=section&id=Consolidated%20Cash%20Flow%20Statement) In Q1 2021, net cash flow from operating activities was negative RMB 11.86 million, with cash and equivalents ending at RMB 791.65 million Key Items of Consolidated Cash Flow Statement (Unit: RMB) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -11,859,300.03 | 28,689,443.33 | | Net Cash Flow from Investing Activities | -114,519,377.01 | -209,158,991.21 | | Net Cash Flow from Financing Activities | 112,301,234.81 | 143,806,944.45 | | Net Increase in Cash and Cash Equivalents | -14,544,663.26 | -33,791,867.41 | | Cash and Cash Equivalents at End of Period | 791,646,821.18 | 613,430,709.79 | [Notes on Financial Statement Adjustments](index=26&type=section&id=Financial%20Statement%20Adjustments) The company adopted the new lease standard in 2021, but no opening balance sheet adjustments were needed due to the nature of its leases - The company implemented the new lease standard starting in 2021, but no adjustments to the opening balance sheet were required as all leases are short-term or low-value[64](index=64&type=chunk)

福安药业（集团）股份有限公司 2020 年年度报告全文 福安药业（集团）股份有限公司 2020 年年度报告 2021 年 03 月 福安药业（集团）股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或者重大遗漏，并承担个别和连带的法律责任。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证本年度报告中财务 报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司特此声明：如本年度报告中涉及未来计划等前瞻性陈述，该计划不构成公司对投资者的实质承诺，投资者及相关人 士均应对此保持足够的风险认识，并且应当理解计划、预测、与承诺之间的差异。 本公司请投资者认真阅读本年度报告全文，并特别注意下列风险因素： 1、行业政策、研发风险 随着"两票制"、 "化学仿制药一致性评价"、"集中带量采购"等政策的出台和逐步实施，将重构医药行业的竞争 逻辑，未来仿制药的销售模式存在调整和变化的不确定性。在医保控费、招标降价等政策影响下，药品价格仍然存在 ...

福安药业（集团）股份有限公司 2020 年第三季度报告全文 福安药业（集团）股份有限公司 2020 年第三季度报告 2020 年 10 月 1 福安药业（集团）股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证 季度报告中财务报表的真实、准确、完整。 2 福安药业（集团）股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,878,679,742.48 | 4,735,968,547.74 | | 24.13% | | 归属于上市公司股东的净资产 | 4,10 ...

福安药业（集团）股份有限公司 2020 年半年度报告全文 福安药业（集团）股份有限公司 2020 年半年度报告 2020 年 08 月 1 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证本半年度报告中财 务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 对半年度报告涉及未来计划等前瞻性陈述的风险提示： 公司特此声明：如半年度报告涉及未来计划等前瞻性陈述，该计划不构成公司对投资者的实质承诺，投资者及相关人士 均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 1、行业政策、研发风险 "两票制"、"化学仿制药一致性评价"、"带量采购"、医保控费、招标降价等行业政策的持续实施，对行业未来的 销售模式、竞争逻辑产生重要影响，销售压力加大、市场竞争加剧，不具备创新能力的药企将面临生存压力。药品研发具有 投入大、周期长、环节多、审评结果不确定的特点，因此如果研发失败、或者获批滞后，则可能导致失去市场机会，研发投 入不能取得预期收益的风险。 应对措施：公司将密切关注宏观政策 ...

福安药业（集团）股份有限公司 2020 年第一季度报告全文 福安药业（集团）股份有限公司 2020 年第一季度报告 2020 年 04 月 1 福安药业（集团）股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证 季度报告中财务报表的真实、准确、完整。 2 福安药业（集团）股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 571,998,133.15 | 726,133,103.37 | -21.23% | | 归属于上市公司股东的净利润（元） | 68,396,960.97 ...

2020 年 03 月 1 福安药业（集团）股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 福安药业（集团）股份有限公司 2019 年年度报告全文 福安药业（集团）股份有限公司 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 2019 年年度报告 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证年度报告中财务报 告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 对年度报告涉及未来计划等前瞻性陈述的风险提示： 公司特此声明：如本年度报告中涉及未来计划等前瞻性陈述，该计划不构成公司对投资者的实质承诺，投资者及相关人 士均应对此保持足够的风险认识，并且应当理解计划、预测、与承诺之间的差异。 本公司请投资者认真阅读本年度报告全文，并特别注意下列风险因素： 1、行业政策、研发风险 "两票制"、"原料与制剂关联审评"、"化学仿制药一致性评价"、"集中带量采购"等政策的出台和逐步实施，对药品生产 经营企业产生重大影响和冲击，未来相关政策的全面推 ...

福安药业（集团）股份有限公司 2019 年第三季度报告全文 福安药业（集团）股份有限公司 2019 年第三季度报告 2019 年 10 月 1 福安药业（集团）股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人汪天祥、主管会计工作负责人余雪松及会计机构负责人(会计主管人员)甘小丽声明：保证 季度报告中财务报表的真实、准确、完整。 2 福安药业（集团）股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 产、衍生金融资产、交易性金融负债、衍生金融负债和其他 债权投资取得的投资收益 | | | | 除上述各项之外的其他营业外收入和支出 | -178,438.38 | | | 减：所得税影响额 | 2,912,541.50 | | | 少数股东权益影响额（税后） | 1,330.95 | | | ...